Form 4: Fractyl Health Director Kelly Ann Barnes Granted Stock Options as Compensation

Fractyl Health, Inc. Director Kelly Ann Barnes was granted 22,500 stock options as compensation for her board service, exercisable at $2.27 per share.

Summary

• Kelly Ann Barnes, a Director of Fractyl Health, Inc. (GUTS), was granted 22,500 stock options on June 11, 2025.
• The stock options have an exercise price of $2.27 per share and an expiration date of June 10, 2035.
• These options were awarded as compensation for her service on the Issuer's board of directors, in accordance with the company's non-employee director compensation policy.
• The options will vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, contingent upon her continued service as a non-employee director through the vesting date.
• Following this transaction, Kelly Ann Barnes beneficially owns 22,500 direct stock options.

Sentiment

Score: 6

Explanation: The document reports a routine compensation grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, as the value of the options increases with the company's stock price.
• This compensation is part of a standard non-employee director compensation policy, indicating structured governance around executive and director remuneration.

Negatives

• No specific negative information is contained within this Form 4 filing, as it primarily reports a routine compensation grant.

Risks

• This Form 4 filing does not detail specific operational or financial risks for Fractyl Health, Inc.; it is a disclosure of an insider transaction.

Future Outlook

The stock options granted to Director Kelly Ann Barnes are subject to future vesting, which will occur in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, provided she continues her service on the board.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, including the healthcare and biotechnology sectors, to attract and retain qualified board members and align their long-term interests with company performance.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity, such as stock options, is a widely accepted industry standard for publicly traded companies.
• While the specific number of options and exercise price are unique to this grant, the mechanism of equity compensation for board service is consistent with global benchmarks for corporate governance and director remuneration.

Corporate Governance

Related Party Transactions

• The grant of stock options to Kelly Ann Barnes, a director of Fractyl Health, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but it primarily serves to align the director's financial interests with the company's long-term stock performance, potentially benefiting shareholders through improved governance and strategic oversight.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 11, 2026), subject to continued board service.
• Following vesting, the director may choose to exercise the options at the specified exercise price before the expiration date of June 10, 2035.

Key Dates

Keywords

Fractyl Health, GUTS, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Board of Directors